In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

Thermo Fisher Scientific has reached a definitive agreement to purchase clinical trial endpoint data solutions provider ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

At CTS Nordics, Arnaud Dourlens explained how Sanofi has engaged between clinical operations and supply teams earlier to ...

Aditya Kotta discussed the biotech funding environment and market trends at OCTSC meeting, in San Diego, California, US. Credits: Athanasios Psimadis / Arena International. The biotech sector has ...

AbbVie’s star immunology asset, Rinvoq, has posted two more Phase III wins – this time in non-segmental vitiligo (NSV). Image credit: Doralin Samuel Tunas via Shutterstock.com. AbbVie may see its star ...

The app helps sites and patients stay synchronised, supporting compliance. Credit: SOMKID THONGDEE/Shutterstock.com. US-based software company Suvoda has launched a unified patient mobile app to ease ...

Zenas BioPharma’s investigational relapsing multiple sclerosis (RMS) asset, obexelimab, has met its primary endpoint in the Phase II MoonStone trial. Image credit: OksanaFedorchuk via Shutterstock.com ...

The double-blind, randomised, vehicle-controlled study enrolled 241 patients. Credit: TY Lim / Shutterstock.com. Incyte has announced results from the Phase IIIb TRuE-AD4 trial of Opzelura ...